<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39565463</PMID><DateCompleted><Year>2025</Year><Month>04</Month><Day>26</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-7322</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Heart failure reviews</Title><ISOAbbreviation>Heart Fail Rev</ISOAbbreviation></Journal><ArticleTitle>Could SGLT2 inhibitors improve outcomes in patients with heart failure and significant valvular heart disease? Need for action.</ArticleTitle><Pagination><StartPage>353</StartPage><EndPage>356</EndPage><MedlinePgn>353-356</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10741-024-10467-x</ELocationID><Abstract><AbstractText>Delivering valvular intervention for all eligible patients with valvular heart disease (VHD) in a timely manner remains a challenge. Therefore, a high number of patients with heart failure (HF) and VHD receive pharmacotherapy while awaiting intervention or as destination therapy if they are deemed inoperable. The sodium-glucose co-transporter-2 inhibitors (SGLT2i) are recommended with a class I indication for patients with chronic HF throughout the spectrum of left ventricular ejection fraction. However, all randomized trials of SGLT2i in HF patients have consistently excluded patients with significant VHD. Considering the proven benefit of SGLT2i for stable outpatients and acutely hospitalized patients with HF, SGLT2i could potentially be used for patients with HF secondary to significant VHD. This article highlights the unmet need to produce robust clinical evidence for the pharmacological management of patients with HF and significant VHD while summarizing the potential benefit from SGLT2i in the management of these patients.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kamperidis</LastName><ForeName>Vasileios</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>1st Department of Cardiology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, AHEPA Hospital, St. Kiriakidi 1, GR 54636, Thessaloniki, Greece. vkamperidis@outlook.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anastasiou</LastName><ForeName>Vasileios</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>1st Department of Cardiology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, AHEPA Hospital, St. Kiriakidi 1, GR 54636, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ziakas</LastName><ForeName>Antonios</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>1st Department of Cardiology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, AHEPA Hospital, St. Kiriakidi 1, GR 54636, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Heart Fail Rev</MedlineTA><NlmUniqueID>9612481</NlmUniqueID><ISSNLinking>1382-4147</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077203">Sodium-Glucose Transporter 2 Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077203" MajorTopicYN="Y">Sodium-Glucose Transporter 2 Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="Y">Heart Failure</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006349" MajorTopicYN="Y">Heart Valve Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013318" MajorTopicYN="N">Stroke Volume</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Medical therapy</Keyword><Keyword MajorTopicYN="N">SGLT2i</Keyword><Keyword MajorTopicYN="N">Valvular heart disease</Keyword></KeywordList><CoiStatement>Declarations. Conflict of interest: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>2</Month><Day>6</Day><Hour>12</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>20</Day><Hour>12</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>20</Day><Hour>11</Hour><Minute>18</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39565463</ArticleId><ArticleId IdType="doi">10.1007/s10741-024-10467-x</ArticleId><ArticleId IdType="pii">10.1007/s10741-024-10467-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M et al (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42(36):3599&#x2013;3726</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehab368</ArticleId><ArticleId IdType="pubmed">34447992</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler J, Packer M, Filippatos G, Ferreira JP, Zeller C, Schnee J et al (2022) Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. Eur Heart J 43(5):416&#x2013;426</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehab798</ArticleId><ArticleId IdType="pubmed">34878502</ArticleId></ArticleIdList></Reference><Reference><Citation>Jhund PS, Kondo T, Butt JH, Docherty KF, Claggett BL, Desai AS et al (2022) Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nat Med 28(9):1956&#x2013;1964</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01971-4</ArticleId><ArticleId IdType="pubmed">36030328</ArticleId><ArticleId IdType="pmc">9499855</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox ZL, Collins SP, Aaron M, Hernandez GA, Iii ATM, Davidson BT et al (2021) Efficacy and safety of dapagliflozin in acute heart failure: rationale and design of the DICTATE-AHF trial. Am Heart J 232:116&#x2013;124</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2020.10.071</ArticleId><ArticleId IdType="pubmed">33144086</ArticleId></ArticleIdList></Reference><Reference><Citation>Biegus J, Voors AA, Collins SP, Kosiborod MN, Teerlink JR, Angermann CE et al (2023) Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial. Eur Heart J 44(1):41&#x2013;50</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehac530</ArticleId><ArticleId IdType="pubmed">36254693</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox ZL, Collins SP, Hernandez GA, McRae AT 3rd, Davidson BT, Adams K et al (2024) Efficacy and safety of dapagliflozin in patients with acute heart failure. J Am Coll Cardiol 83(14):1295&#x2013;1306</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2024.02.009</ArticleId><ArticleId IdType="pubmed">38569758</ArticleId></ArticleIdList></Reference><Reference><Citation>Iung B, Delgado V, Rosenhek R, Price S, Prendergast B, Wendler O et al (2019) Contemporary presentation and management of valvular heart disease: the EURObservational Research Programme Valvular Heart Disease II Survey. Circulation 140(14):1156&#x2013;1169</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.119.041080</ArticleId><ArticleId IdType="pubmed">31510787</ArticleId></ArticleIdList></Reference><Reference><Citation>Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J et al (2022) 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 43(7):561&#x2013;632</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehab395</ArticleId><ArticleId IdType="pubmed">34453165</ArticleId></ArticleIdList></Reference><Reference><Citation>Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F et al (2021) 2020 ACC/AHA Guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 77(4):450&#x2013;500</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.11.035</ArticleId><ArticleId IdType="pubmed">33342587</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascual-Figal DA, Zamorano JL, Domingo M, Morillas H, Nu&#xf1;ez J, Cobo Marcos M et al (2023) Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: the DAPA-MODA study. Eur J Heart Fail 25(8):1352&#x2013;1360</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.2884</ArticleId><ArticleId IdType="pubmed">37211950</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MMY, Brooksbank KJM, Wetherall K, Mangion K, Roditi G, Campbell RT et al (2021) Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation 143(6):516&#x2013;525</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.052186</ArticleId><ArticleId IdType="pubmed">33186500</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, Garcia-Ropero A, Mancini D, Pinney S et al (2021) Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction. J Am Coll Cardiol 77(3):243&#x2013;255</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.11.008</ArticleId><ArticleId IdType="pubmed">33197559</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka H, Soga F, Tatsumi K, Mochizuki Y, Sano H, Toki H et al (2020) Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure. Cardiovasc Diabetol 19(1):6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-019-0985-z</ArticleId><ArticleId IdType="pubmed">31910853</ArticleId><ArticleId IdType="pmc">6947966</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajmone Marsan N, Delgado V, Shah DJ, Pellikka P, Bax JJ, Treibel T et al (2023) Valvular heart disease: shifting the focus to the myocardium. Eur Heart J 44(1):28&#x2013;40</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehac504</ArticleId><ArticleId IdType="pubmed">36167923</ArticleId></ArticleIdList></Reference><Reference><Citation>Asrial AA, Reviono R, Soetrisno S, Setianto BY, Widyaningsih V, Nurwati I et al (2023) Effect of dapagliflozin on patients with rheumatic heart disease mitral stenosis. J Clin Med 12(18):5898</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12185898</ArticleId><ArticleId IdType="pubmed">37762839</ArticleId><ArticleId IdType="pmc">10532082</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang DH, Park SJ, Shin SH, Hwang IC, Yoon YE, Kim HK et al (2024) Ertugliflozin for functional mitral regurgitation associated with heart failure: EFFORT trial. Circulation 149(24):1865&#x2013;1874</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.124.069144</ArticleId><ArticleId IdType="pubmed">38690659</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhingra N, Verma S, Butler J (2024) SGLT2 inhibition in subjects with valvular heart disease: a pooled analysis of the EMPEROR program. Am Assoc Thorac Surg</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>